骨髓增殖性肿瘤 中国就医指南

Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders characterized by the overproduction of mature blood cells—primarily red blood cells, white blood cells, and/or platelets—in the bone marrow. The classic Philadelphia chromosome–negative MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). These conditions arise from acquired somatic mutations—most commonly in the JAK2 gene (present in >95% of PV and ~60% of ET/PMF cases), but also in CALR and MPL—leading to constitutive activation of the JAK-STAT signaling pathway and uncontrolled myeloid proliferation. While the exact triggers remain unclear, aging is the strongest epidemiologic correlate: MPNs predominantly affect adults over age 60, with median diagnosis ages ranging from 60 to 65 years. Incidence estimates vary globally but average approximately 1–2 cases per 100,000 person-years for PV and ET, and 0.5–1.5 per 100,000 for PMF. Prevalence is higher due to chronic disease course—estimated at 22–57 per 100,000 for PV and ET, and up to 10 per 100,000 for PMF. Risk factors include advancing age, male sex (slightly higher incidence in PV and PMF), and possibly environmental exposures such as ionizing radiation or benzene; however, no strong hereditary pattern or modifiable lifestyle risk has been consistently established. Importantly, MPNs are not contagious nor caused by infection. Quality of life is significantly impacted—not only by physical symptoms (e.g., fatigue, pruritus, night sweats, early satiety, bone pain, splenomegaly-related discomfort) but also by psychological burden, including anxiety about thrombotic events, disease progression to acute myeloid leukemia (10–20% lifetime risk in PMF), and treatment-related side effects. Patients often report impaired work productivity, sleep disruption, and social withdrawal. Symptom burden correlates poorly with blood counts, underscoring the importance of patient-reported outcomes in clinical assessment. Long-term management focuses on risk stratification (age, prior thrombosis, mutation profile, blood counts), cytoreduction (hydroxyurea, interferon-alpha, ruxolitinib), anticoagulation, and supportive care—including phlebotomy in PV and transfusion support in advanced myelofibrosis. With modern therapies, many patients live for decades, especially those with ET or low-risk PV; however, PMF carries a more variable prognosis, with median survival ranging from 1.5 to 15+ years depending on molecular and clinical risk factors.

# 骨髓增殖性肿瘤（MPN）治疗方案与费用明细（血液科）

一、非手术/药物/保守治疗

适用人群：早期真性红细胞增多症（PV）、原发性血小板增多症（ET）、低危原发性骨髓纤维化（PMF）患者。

• •一线药物治疗（羟基脲、干扰素α-2b、芦可替尼）：年药费 3.6万–18.5万元（国产羟基脲约0.2万元/年；进口芦可替尼医保后约6.8万/年，自费12.8–18.5万元）
• •常规监测：血常规+外周血涂片+JAK2/V617F等基因检测（1200–2800元/次），骨髓穿刺活检（2600–4200元/次）

二、手术/介入治疗

适用人群：高危PMF伴脾亢需减瘤或门脉高压并发症者。

• •脾切除术（开腹/腹腔镜）：手术费+麻醉+住院（7–14天）4.2万–7.5万元；术前检查（CT+心肺功能+凝血谱等）2800–4500元
• •脾动脉栓塞术（微创介入）：含DSA、栓塞材料、住院（5–8天）3.8万–6.3万元

三、特殊复杂/晚期方案

• •异基因造血干细胞移植（唯一可能根治手段）：适用于≤65岁、高危MF或加速期患者；全流程（供者筛选、预处理、移植、GVHD防治、ICU监护）35万–62万元（医保报销后个人负担约12万–28万元）
• •临床试验用药（如新型JAK抑制剂、BCL-2抑制剂）：部分项目免药费，仅收检查及住院费 1.5万–3.2万元/周期

方案快速选择指南

✅ 预算有限/初诊低危者：首选羟基脲+规律随访（年支出≤0.8万元） ✅ 中高危/症状明显者：芦可替尼联合基因监测（年支出6.8万–12.8万元） ✅ 年轻高危/进展期患者：评估移植可行性，优先纳入医保定点移植中心